COVID-19 Therapeutics Warmline
1-866-268-4322 (866-COVID-CA) Provider Warmline Support Now Available. May end June 30, 2023, check back for updates.
Beginning January 9, 2023, health care providers can call 1-866-268-4322 (COVID-CA) to receive free and confidential consultation on COVID-19 testing and treatment. The COVID-19 Therapeutics Warmline is a real-time resource available to all California health care providers and is managed by the University of California, San Francisco (UCSF) National Clinician Consultation Center.
Available Monday through Friday, 6 a.m. – 5 p.m. (Voicemail messages left after hours will be returned on the next business day.)
Moderate to severe immunocompromised patients: Per the CDC: "As of January 26, 2023, EVUSHELD is not authorized for emergency use because it is unlikely to be active against the majority of SARS-CoV-2 variants circulating in the United States." However, identifying moderately to severely immunocompromised members, who are at high risk of serious illness with COVID-19 infection, remains very important.
These individuals should be encouraged to have a COVID-19 plan in place, in the event they are exposed or develop symptoms of COVID-19. This would include planning for prompt access to testing and treatment. Partnership has reached out to many of these members to provide education about risk and to recommend they contact their provider to formulate a plan. Your efforts to do the same in your clinical setting will increase the odds that these vulnerable patients will have the information needed to help protect themselves from serious disease. The CDC guidelines as to which patients fit into these categories may be found below.
Testing: Please note that while all individuals who are 50 years of age and older, as well as those with high risk or very high risk conditions (links below) are strongly encouraged to seek treatment, all individuals 12 years and older are eligible for treatment. Prompt testing not only helps to limit exposures to others but also affords an opportunity for higher risk individuals to access timely treatment. Listed below are some useful links.
Note: Oral therapeutics are available through Medi-Cal Rx mail order. Short time frames for beginning effective treatment makes use of mail ordering prescriptions challenging as routine deliveries may take 7-10 days. However, 1-2 day shipping is offered by some retail chains. Providers will need to verify delivery time frames available locally before using this resource.
Infusion Centers Offering COVID-19 Therapeutics: Evusheld and Bebtelovimab are not currently authorized
for use by the FDA for COVID-19 prophylaxis or treatment. A list of all sites
offering Remdesivir is not currently available through federal or CDPH
websites; Partnership's list of sites which have billed for Remdesivir infusion
may be found below. In addition, providers are encouraged to reach out to their
local hospital, infusion centers, or local health department to identify access
points for Remdesivir infusion.
Treatment Resouces for Providers:
